Upload
healthegy
View
522
Download
0
Embed Size (px)
Citation preview
© 2016 Glaukos Corporation
1
GLAUKOS: TAKING A MIGS COMPANY PUBLIC
Chris Calcaterra, Chief Commercial Officer OIS@ASCRS -- May 5, 2016
© 2016 Glaukos Corporation
2
GLAUKOS INITIAL PUBLIC OFFERING: JUNE 25 2015
MIGS GOES TO WALL STREET
© 2016 Glaukos Corporation
3
• Completed initial public offering on June 25, 2015
• Shares currently trade on New York Stock Exchange under ticker symbol GKOS
NYSE: GKOS
© 2016 Glaukos Corporation
4
The Lead Up
• Founded, built and validated MIGS category over a 15+ year period
• Selected bankers and other key advisors • Worked closely with advisors to prepare offering documents
that described strategy, growth prospects, strengths and risks
• Continually evaluated market conditions to identify optimal IPO timing
• Prepared for more rigorous financial reporting, ongoing public disclosure and compliance with securities laws and regulations
• Expanded board and established new management functions
• Prepared the organization for life as a public company• Required more than a year of intense preparation, while
continuing to run/grow the business
© 2016 Glaukos Corporation
5
• Met with approx. 140 investors to answer questions and explain strategy, potential, competitive strengths and success factors
• Covered 9 cities in 7 days• Strong institutional investor interest:
– First-mover advantage; MIGS pioneer – Novel technology platform that addresses
true unmet need – Demonstrated track record of operational
execution and financial performance– Deep, late-stage product pipeline
The Roadshow
© 2016 Glaukos Corporation
6
Day One
• Sold 6.9 million newly issued shares
• Priced at $18, $3 above initial pricing range
• Shares rose 70% on first trading day
• Raised $113.6 million in net proceeds
© 2016 Glaukos Corporation
7
Wall Street Views on MIGSStrong Support For Glaukos Novel Strategy: iStent® + Cataract Surgery
“The cataract + MIGS procedure takes a patient
who is already having eye surgery and adds in a
layer of clinical efficacy at essentially no
additional risk, no additional cost to the patient,
and no additional inconvenience … Given the
strong incentives supporting MIGS adoption, we
see significant runway for rapid market growth…
“
© 2016 Glaukos Corporation
8
Wall Street Views on MIGSWide Recognition Of Robust Glaukos And iStent® Growth
“We came away from this year’s AAO with a belief that
MIGS will continue to represent a rapidly growing
market … A theme we heard consistently was that the
introduction of iStent has allowed physicians to have
more options in treating patients and has a clear place
in the treatment paradigm.
“
© 2016 Glaukos Corporation
9
Wall Street Views on MIGS
“MIGS is hot. The MIGS space has seen two
acquisitions in the last six months… “
A View That Glaukos’s Success Has Attracted Followers Into The MIGS Space
© 2016 Glaukos Corporation
10
Taking a MIGS Company Public
• Providing higher public profile and awareness of the MIGS space
• Helping to establish market valuations for MIGS technology and opportunity
• Providing capital to invest in continuing development of burgeoning MIGS market/treatment class
© 2016 Glaukos Corporation
11
NYSE TRADERS AWAIT THE OPEN OF GKOS STOCK: JUNE 25, 2015
MIGS GOES TO WALL STREET